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Abstract
Background: Cigarette smoking is one of the major preventable causes of death and diseases in Qatar. The study
objective was to test the effect of a structured smoking cessation program delivered by trained pharmacists on
smoking cessation rates in Qatar.
Methods: A prospective randomized controlled trial was conducted in eight ambulatory pharmacies in Qatar.
Eligible participants were smokers 18 years and older who smoked one or more cigarettes daily for 7 days, were
motivated to quit, able to communicate in Arabic or English, and attend the program sessions. Intervention group
participants met with the pharmacists four times at 2 to 4 week intervals. Participants in the control group received
unstructured brief smoking cessation counseling. The primary study outcome was self-reported continuous
abstinence at 12 months. Analysis was made utilizing data from only those who responded and also using
intent-to-treat principle. A multinomial logistic regression model was fitted to assess the predictors of smoking at
12 months. Analysis was conducted using IBM-SPSS® version 23 and STATA® version 12.
Results: A total of 314 smokers were randomized into two groups: intervention (n = 167) and control (n = 147).
Smoking cessation rates were higher in the intervention group at 12 months; however this difference was not
statistically significant (23.9% vs. 16.9% p = 0.257). Similar results were observed but with smaller differences in the
intent to treat analysis (12.6% vs. 9.5%, p = 0.391). Nevertheless, the daily number of cigarettes smoked for those
who relapsed was significantly lower (by 4.7 and 5.6 cigarettes at 3 and 6 months respectively) in the intervention
group as compared to the control group (p = 0.041 and p = 0.018 respectively). At 12 months, the difference was 3.
2 cigarettes in favor of the intervention group but was not statistically significant (p = 0.246). Years of smoking and
daily number of cigarettes were the only predictors of smoking as opposed to quitting at 12 months (p = 0.005;
p = 0.027 respectively).
Conclusions: There was no statistically significant difference in the smoking cessation rate at 12 months between
the groups. However, the smoking cessation program led to higher (albeit non-significant) smoking cessation rates
compared with usual care. More research should be conducted to identify factors that might improve abstinence.
Trial registration: Clinical Trials NCT02123329. Registration date 20 April 2014
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Background
Tobacco use is one of the major public health threats in
the world [1]. It is responsible for killing globally around
six million people a year, and current trends indicate that
this number will increase to more than eight million
deaths per year by 2030 [2]. Cessation of tobacco use is as-
sociated with significant health benefits [3]. The World
Bank suggests that around 180 million tobacco related
deaths could be prevented between now and 2050 if adult
tobacco consumption decreased by 50% by 2020 [4]. How-
ever, quitting tobacco use can be very challenging without
assistance from healthcare professionals. Evidence con-
firms that tobacco cessation interventions provided by
healthcare practitioners are more effective when com-
pared to self-help [5]. Pharmacists are easily accessible by
the public and pharmacologic tobacco cessation aids have
become increasingly available over the counter in pharma-
cies. Accordingly, pharmacists have a great opportunity to
play a significant tobacco cessation role in the community
[6, 7]. Pharmacist-provided tobacco cessation services in
the community and ambulatory settings have been de-
scribed in the literature, and these included randomized
controlled trials, before-and-after studies, or single arm
studies. Tobacco cessation services which included indi-
vidualized counseling or within-group sessions have re-
sulted in better smoking abstinence as compared with
usual care. Abstinence has been either self-reported or
biochemically verified using exhaled carbon monoxide,
salivary or urinary cotinine levels [7–14].
The International Pharmaceutical Federation (FIP)
published a statement of policy that outlines the antici-
pated role of pharmacists in eliminating the use of
tobacco in the communities they serve. As per this state-
ment, the pharmacist should provide tobacco cessation
services to anyone who is considering quitting tobacco
use or to anyone who suffers from tobacco-induced dis-
eases [15]. The EuroPharm Forum in collaboration with
the World Health Organization (WHO) Tobacco Unit
issued a practical guide in which pharmacists were
encouraged to become involved in tobacco cessation
through helping and motivating people to quitting
smoking, to offering extensive smoking cessation
services [16]. The clinical practice guidelines for treating
tobacco use and dependence developed by the U.S.
Department of Health and Human Service recom-
mended that clinicians (including pharmacists) intervene
with any patient who uses tobacco [5]. In the American
Society of Health-System Pharmacists’ (ASHP) Thera-
peutic Position Statement on the Cessation of Tobacco
Use, healthcare providers, including pharmacists, were
highly endorsed to improve the health of their patients
by incorporating into their daily practice the identifica-
tion of patients who use tobacco and the delivery of
tobacco cessation services [17].
Tobacco use is one of the major preventable causes of
death and disease in Qatar. According to the 2013
Global Adult Tobacco Survey (GATS), 20.2% of men in
Qatar currently smoke tobacco and more than two fifths
(41.5%) of current smokers report having their first
smoke within half an hour of waking up [18]. In
addition, 22.8% of boys aged 13 to 15 years currently use
some form of tobacco products as per the 2013 Global
Youth Tobacco Survey (GYTS) [19]. Notably, tobacco
related diseases, including cardiovascular diseases
(CVDs), are very common in Qatar. Ischemic heart dis-
ease is the leading cause of death in Qatar, accounting
for 0.4 thousand deaths in 2012 [20]. Moreover, in the
period from 1991 and 2006, lung cancer was ranked as
one of the leading cancers in men with an incidence rate
of 5.9 per 100,000 population [21]. It has been reported
that on the average, 65 million dollars are spent on ciga-
rettes per year in Qatar with 150 million dollars spent
annually to cover the healthcare cost of smoking related
diseases [22]. To decrease tobacco use, Qatar govern-
ment has endorsed the Framework Convention on
Tobacco Control (WHO FCTC) and has implemented
several tobacco control activities [23]. There is a great
opportunity for Qatar pharmacists to combat this public
health burden. More than 700 pharmacists are currently
working in ambulatory care clinics and in community
pharmacies in Qatar. Nevertheless, ambulatory and com-
munity pharmacists in Qatar are not entirely involved in
tobacco cessation activities. Only 21% of pharmacists in
Qatar frequently ask patients about their smoking status,
only 47% offer counseling to nicotine replacement ther-
apy (NRT) purchasers, but more than 80% are interested
in providing smoking cessation counseling [24]. Qatar
pharmacists’ positive attitudes toward smoking cessation
counseling can be translated into action if there is any
existing smoking cessation model that pharmacists can
utilize in their day to day practice. However, to date an
intensive patient-specific program of smoking cessation
that is designed exclusively for implementation in
community and ambulatory pharmacies in Qatar does
not exist.
The current study’s objective was to test the effect of a
face-to-face structured patient-specific smoking cessa-
tion program delivered by trained ambulatory pharma-
cists on smoking cessation rates in Qatar.
Methods
The study methodology is available in details in the pub-
lished study protocol [25].
Study design
The study was a prospective randomized controlled trial
that compared the effectiveness of a face-to-face
structured patient-specific smoking cessation program
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conducted by trained ambulatory pharmacists with brief
unstructured pharmacist-delivered advice on smoking
cessation rates.
Study setting
The study was implemented in eight public and private
ambulatory pharmacies in Qatar. Two pharmacists from
each site were invited to participate in the study.
Study pharmacists’ training
Before starting the study, a copy of the study method-
ology was sent to each study pharmacist along with lit-
erature on smoking cessation. Three weeks later, the
study pharmacists attended a 2-day (8 h/day) smoking
cessation training workshop.
The workshop was organized by the Hamad Medical
Corporation (HMC) smoking cessation clinic team and
Qatar University (QU) College of Pharmacy. The train-
ing team consisted of a public health and disease control
consultant (who is also the HMC smoking cessation
clinic head), academic faculty members with expertise
and interests in tobacco cessation from teaching and
research perspectives, and an international expert in the
area of tobacco cessation.
The workshop included the following elements: smok-
ing epidemiology and risks, benefits of quitting, trans-
theoretical model for behavior change, behavioral
modification techniques, classification of smokers
according to their stage of change, NRT, patient counsel-
ing techniques, development of a personalized action
plan, program methodology and other needed elements.
In addition, the study team went over the study proto-
col with the pharmacists including participant group
allocation, how to deliver the intervention and what to
do with control patients.
Pharmacists were trained to help smokers identify the
situations that may trigger craving to smoke and to pro-
vide them with strategies to improve coping [26]. More-
over, the pharmacists were educated to provide the
smokers with information on what to expect during quit
attempts and to address any concerns that patients may
have [27].
Pharmacists were further trained on how to document
the patient’s smoking status, medical and medication
history, basic demographic characteristics, stage of
change, education, follow-up and the agreed personal-
ized action plan to quit smoking. In addition, they were
taught how to fill the Fagerstrom test for nicotine
dependence (FTND). The FTND is a six-item question-
naire designed to determine a patient’s degree of
nicotine dependence [28]. This questionnaire has already
been used in smoking-related studies in the Middle East
[29, 30].
Study advertising
The study pharmacists were encouraged to identify any
opportunity to promote the smoking cessation program.
For instance, they were advised to ask patients about
their smoking status and to inform them about the
smoking cessation program when filling prescriptions.
Furthermore, study pharmacists were provided with
posters and leaflets to display at their sites or to hand to
clients. Moreover, letters were sent to the general practi-
tioners and dentists practicing in the study’s ambulatory
clinics inviting them to refer to the pharmacy any
smoker who expresses interest (or is considering) to quit
smoking.
Screening and eligibility criteria
Smokers who were interested in quitting met with the
study pharmacists who in turn assessed their eligibility
for inclusion in the study. The screening and enrollment
of participants was done by the study pharmacists at the
sites on a patient by patient basis. Eligible participants
were any patients aged 18 years and older who smoked
one or more cigarettes daily for 7 days, were motivated
to quit, were able to communicate in Arabic or English,
and were willing and able to attend the scheduled ses-
sions at the study pharmacies. The motivation to quit
was determined by the pharmacist using the trans-
theoretical model of behavior change [31].
Exclusion criteria were (1) use of other nicotine or to-
bacco products; (2) current use or use in the last 30 days
of smoking cessation aids or medications; (3) planning
to leave Qatar in the next 12 months; (4) presence of
any major medical condition that would prevent use of
the NRT; (5) pregnancy; and (6) psychiatric illness or an-
other debilitating condition that would interfere with
participation in the study.
Study enrollment
After the screening process was completed, the study
pharmacist provided the eligible participant with rele-
vant information on the smoking cessation program and
explained the potential benefits and risks of participa-
tion. Before enrollment in the study, the participant was
requested to sign an informed consent form. Once this
form was signed, the pharmacist scheduled an appoint-
ment with him or her at dates and times that were
appropriate for both of them.
Randomization
Randomization was made using a sealed envelope tech-
nique. Permuted block randomization method with
block of size 2 and 4 was used. The sequences were gen-
erated by the study statistician using a computer pro-
gram from the website randomization.com (http://
www.randomization.com). Independent sequences were
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generated for the different study pharmacists. Serially
numbered, opaque, sealed randomization envelopes were
then provided to each study pharmacist. The study
statistician was not involved in recruitment of partici-
pants or in data collection. The envelope with the lowest
number of randomized treatment blocks was opened by
the pharmacist upon inclusion of each new participant.
Initial appointment
At the initial appointment, which took 30 min, the study
pharmacist collected information regarding the partici-
pant’s sociodemographic characteristics, current medical
problems and medications, smoking history and vital
signs. In addition, the pharmacist measured the partici-
pant’s exhaled carbon monoxide (CO) level using CO
smokerlyzer. Moreover, the pharmacist assessed his or
her nicotine dependence using the FTND. The partici-
pant was then randomly assigned to one of two groups:
intervention group or control group based on the
randomization sequence that was anonymously set earl-
ier by the study statistician for each study pharmacist.
Participant was informed of his or her group allocation.
A new appointment was scheduled with participants in
the intervention group. Brief unstructured smoking
cessation advice was given to participants in the control
group.
Intervention group
Smokers assigned to the intervention group participated
in a face-to-face one to one four-session program at the
pharmacy by the study pharmacist at 2 to 4-week inter-
vals over 8 weeks.
First session
The first session took around 30 min. In this session, the
study pharmacist facilitated the participant’s preparation
to quit. The participant selected a quit date in the next
2–4 weeks. The pharmacist explained to the participant
the benefits of smoking cessation and offered him/her
tailored behavioral and lifestyle strategies. The pharma-
cist also discussed with the participant what to expect
during the quit attempt and provided him or her with
strategies to cope with the early days of quitting.
NRT was provided to the participant as a patch or loz-
enge based on his or her prior experience, preference
and the medication side effect profile. Before the NRT
was dispensed to the participant, the study pharmacist
checked if the participant had any contraindications to
nicotine therapy and was not currently using any medi-
cation that would interact with NRT. The participant
started the NRT on his or her chosen quit date. The
study pharmacist counseled the participant about the
dosage regimen, administration, duration of therapy,
adverse effects, drug interactions, and disposal of NRT.
Participants who were given the nicotine patch started
at 21 mg if they smoked 10 cigarettes or more per day.
Otherwise, they received a 14-mg patch. Both dosages
were continued for 6 weeks before being tapered. The
21-mg patch was decreased to 14 mg, continued for
2 weeks and then decreased to 7 mg for the final
2 weeks. Patients who started with the 14-mg patch were
tapered to 7 mg for the final 2 weeks [32]. Participants
who preferred the nicotine lozenge used the 1-mg pieces
for 6 weeks as one lozenge every 1–2 h before tapering.
Then the participants took one lozenge every 2–4 h for
weeks 7 to 9, then one lozenge every 4–8 h for week 10
to 12 [33]. The pharmacist also designed a personalized
action plan for each participant.
Follow-up sessions
The first follow-up session was scheduled 1 week after
the participant’s set quit day and took around 20 min. In
this session, the pharmacist evaluated the participant’s
smoking status and NRT tolerability and measured his
or her vital signs and exhaled CO level. If the participant
was successful in quitting, the pharmacist offered
reinforcement and addressed any concerns related to
quitting. If the participant failed to quit, the pharmacist
cautiously assessed the participant’s quit attempt and
targeted all recognized obstacles. If the participant did
not tolerate the NRT, the pharmacist recommended that
the participant would stop the NRT and would visit the
HMC smoking cessation clinic for additional support. In
this case, the participant was considered withdrawn from
the study.
The second follow-up session was scheduled 2 weeks
after the first follow-up session. The third follow-up ses-
sion was set 4 weeks after the second follow-up session.
In these sessions, which were 10 to 15 min long, the
pharmacist assessed the participant’s smoking status,
vital signs, exhaled CO level, NRT tolerability and pro-
vided NRT refills. In addition, the pharmacist used
cognitive-behavioral strategies to prevent relapse. After
the third and last follow-up session, the participant was
invited to contact the pharmacist in case he or she
needed any further support.
Control group
Participants in the control group received 5 to 10 min of
unstructured one to one brief smoking cessation coun-
seling by the pharmacist emulating current practice.
They were also provided with educational materials
about smoking cessation and were offered NRT in case
of no documented contraindications or drug-drug inter-
actions. The NRT dosage regimen and duration of
therapy were similar to the ones used in the intervention
group. Control participants did not attend any follow-up
sessions.
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Outcome measures
Research assistants, who were blinded to the study par-
ticipants’ group allocation, contacted the participants by
phone and assessed the following outcome measures at
3, 6 and 12 months post the participants’ enrollment
dates in the study:
 Self-reported 7-day point prevalence abstinence,
defined as having smoked no cigarettes for the
previous 7 days
 Self-reported 30-day point prevalence abstinence
defined as having smoked no cigarettes in the last
30 days
 Self-reported continuous abstinence defined as
having smoked no cigarettes since quit day
To objectively determine long-term abstinence, at
12 months, participants who self-reported not smoking
were invited to come to their study clinic to measure
their exhaled CO level by the clinic nurse who was
blinded to the participants’ group. Participants were con-
sidered abstinent if they register less than 6 ppm (parts
per million) on the test [34].
In case the participants were still smoking at each as-
sessment point, they were asked about the number of
cigarettes smoked per day and about the reasons for not
stopping using open ended questions.
The study primary outcome was self-reported continu-
ous abstinence at 12 months. Secondary outcomes in-
cluded: 7-day point prevalence, 30-day point prevalence
and continuous abstinence at 3 months and at 6 months
and 7-day point prevalence and 30-day point prevalence
abstinence at 12 months.
Data analysis
The CONSORT guidelines were followed when analyz-
ing the study data [35]. Demographic characteristics and
other smoking related variables were summarized using
frequency distributions (for categorical variables) and
means with standard deviations (for numeric variables)
and were compared between the two groups using the
chi-squared test (or alternatively the Fisher’s exact test
for small cell counts) for categorical variables and the
independent t-test (or alternatively the Wilcoxon rank
sum test for non-normally distributed variables) for
numerical variables.
The primary study outcome was self-reported continu-
ous abstinence at 12 months. Verification by the CO test
at 12 months was not used as part of the primary outcome
as was planned in the original study protocol since only 8
participants returned for their CO measurements. The
percentages of participants achieving the primary outcome
were computed and compared between the two groups
using the chi-squared test. Moreover, the difference in the
proportions of continuous abstinence at 12 months be-
tween the two study groups (with 95% confidence inter-
vals) was computed along with the number needed to
treat (computed as 1 divided by the difference in the pro-
portions of the primary outcome between the two study
arms). Multiple logistic regression was used to obtain the
odds ratio of the primary outcome between the two study
groups adjusting for any imbalances in demographic or
other variables. In addition, mixed effects logistic regres-
sion, with pharmacy-level random effect, was considered
to adjust for the possible pharmacy effect if it existed. The
main regression for the primary outcome was also ad-
justed for the number of monitoring visits that the partici-
pants attended to assess the adherence effect. The
analyses of the primary and secondary outcomes were
done using responders only and also using the intent-to-
treat principle whereby participants who were lost to
follow-up were classified as smokers.
Differences in abstinence between the study groups
were also assessed at 3 and 6 months using the
Chi-squared test or Fisher’s exact test. For those who re-
lapsed at 3, 6 and 12 months, the number of cigarettes
smoked daily was summarized using means and standard
deviations and compared between the study groups in a
similar way to other numeric variables described above.
According to the self-reported abstinence outcome at
12 months; participants were divided into 3 groups: ab-
stainers, smokers and dropouts. Dropouts included those
who were lost to follow up at 12 months. A multinomial
logistic regression model was fitted with this new vari-
able as the dependent variable and several independent
variables including demographic, baseline smoking
related variables and study group (similar to what is sug-
gested by Borelli et al., 2002) [36]. The model allowed
for the simultaneous detection of predictors for those
who smoked and those who dropped out from the study.
Results were summarized using Relative Risks Ratios
along with 95% confidence intervals and p-values. Statis-
tical analyses were conducted using the IBM-SPSS ver-
sion 23 and STATA version 12. In all analyses, the level
of significance was set at 5%.
Sample size calculation
For a priori sample size calculation, we assumed a 7-day
point prevalence abstinence at 12 months of 3% for the
control group and 15% for the intervention group based
on the results of one of the previous pharmacist-run
smoking cessation studies. With a two-sided alpha of 5%
and 90% power, a minimum sample size of 118 partici-
pants was estimated for each group.
Continuous quality improvement and evaluation plan
At all stages of the study implementation, the study
pharmacists were closely supervised by the study team.
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Supervision was through several mechanisms including
meetings, communication and site visits.
Results
Between February 2013 and December 2014, the study
pharmacists assessed 450 smokers for eligibility in the
study. Of them, 361 (80.2%) met the study inclusion cri-
teria. A total of 314 cigarette smokers consented to en-
roll in the study and were randomized into one of two
study groups (Fig. 1). Of 167 participants in the inter-
vention group, 55% completed two pharmacy visits. Two
patients in the intervention group could not tolerate
NRT and as a result they were excluded by the study
pharmacists.
Out of the 314 recruited participants, 171 (54.5%)
were assessed at 12 months follow up and 136 (43%)
participants were assessed at 3, 6 and 12 months. Only 8
(6 in the intervention arm and 2 in the control arm) of
the 35 participants who self-reported abstinence at
12 months had a final CO measurement taken (22.9%)
and results showed that all those 8 participants were
nonsmokers.
Participants were mainly men (97.8%) below the age of
40 years (59.3%), had been smoking for more than
10 years (68.4%), had a FTND score of more than 5
(61.1%) and had tried quitting before (69.5%). Except for
nationality, previous quit attempts and having diabetes;
demographic, tobacco related, and clinical variables were
comparable between the two study groups (Table 1).
The percentage of participants reporting abstinence at
12 months was slightly higher in the intervention group
as compared to the control group, however this differ-
ence didn’t reach statistical significance (23.9% vs. 16.9%,
Diff = 7.0%, 95% CI −5.2%, 18.9%, Number Needed to
Treat = 15 and p = 0.257). When restricting the analysis
to those who had complete data on all follow up assess-
ments, a similar trend was observed but with a smaller
difference between the study groups. Results of
Fig. 1 Participant flow chart
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comparing continuous abstinence at 3 months and
6 months assessment showed lower differences between
the two groups (Table 2). Intent to treat analysis for the
primary outcome where participants with missing data
were considered smokers also revealed nonsignificant
difference between the two study arms (12.6% vs.
9.5% in the intervention arm and control arm
respectively, p = 0.391, NNT = 33) (Table 2).
The main analysis did not change when adjusted for the
possible clustering effect by the pharmacists, for observed
imbalances in demographic and smoking related variables
and for the number of attended monitoring visits, or when
all those lost to follow up were considered smokers. For
example, the unadjusted OR of 1.54 (95% CI 0.73, 3.29)
changed to 1.62 (95% CI 0.65, 4.04) and p = 0.297 when it
was adjusted for years of smoking, cigarettes per day, tried
quitting before, diabetes and nationality (Table 3).
The average daily number of cigarettes smoked for
those who relapsed was significantly lower by 4.7 and
5.6 cigarettes at 3 and 6 months respectively in the
Table 1 Demographic and tobacco use variables compared
between the two study groups
Variable Intervention (N = 167) Control (N = 147) p-value
Age in years 0.221
18–29 40 (24.5%) 33 (23.2%)
30–39 53 (32.5%) 55 (38.7%)
40–49 46 (28.2%) 27 (19.0%)
50 and above 24 (14.7%) 27 (19.0%)
Gender (males) 164/167 (98.2%) 143/147 (97.3%) 0.710
Nationality 0.006*
Qatar 25 (15.4%) 36 (24.8%)
Egypt 41 (25.3%) 49 (33.8%)
Other 96 (59.3%) 60 (41.4%)
Highest educational level 0.604
Primary 15 (9.3%) 16 (11.3%)
Secondary/high
school
40 (24.8%) 43 (30.3%)
College diploma 40 (24.8%) 37 (26.1%)
Undergraduate
degree
49 (30.4%) 33 (23.2%)
Post graduate
degree
17 (10.6%) 13 (9.2%)
Marital Status 0.389
Never married 32 (19.6%) 23 (15.9%)
Ever married 131 (80.4%) 122 (84.1%)
Years of cigarettes smoking 0.527
0 to 2.99 years 4 (2.4%) 7 (4.8%)
3 to 4.99 years 13 (7.9%) 15 (10.3%)
5 to 10 years 30 (18.3%) 29 (19.9%)
More than
10 years
117 (71.3%) 95 (65.1%)
Number of cigarettes per day 0.227
Mean(sd) 21.6 (11.9) 23.5 (13.6)
Tried quitting before
(Yes)
122/163 (74.8%) 92/145 (63.4%) 0.030*
Family member
smokes (yes)




51/164 (31.1%) 31/145 (21.4%) 0.053
Hypertension 20/164 (12.2%) 15/145 (10.3%) 0.609
Diabetes 27/164 (16.5%) 12/145 (8.3%) 0.031*
Asthma/chronic
lung diseases
6/164 (3.7%) 4/145 (2.8%) 0.755
Cardiovascular
diseases
5/164 (3.0%) 3/144 (2.1%) 0.728
Gastrointestinal
diseases
4/164 (2.4%) 4/145 (2.8%) 0.999
Depression 2/164 (1.2%) 0/145 (0.0%) 0.500
Table 1 Demographic and tobacco use variables compared
between the two study groups (Continued)
Physical Exercise 0.999
No 66 (41.8%) 59 (41.8%)
Yes but irregularly 62 (39.2%) 55 (39.0%)
Yes regularly 30 (19.0%) 27 (19.1%)
Most important reasons for quitting†
Religious reasons 55/129 (42.6%) 58/124 (46.8%) 0.508
To live healthier 88/152 (57.9%) 76/135 (56.3%) 0.785
To live longer 21/127 (16.5%) 25/121 (20.7%) 0.403
To be role model
to children
30/132 (22.7%) 28/116 (24.1%) 0.793




8/109 (7.3%) 11/106 (10.4%) 0.433
Baseline heart rate 0.810
Mean(sd) 79.0 (13.6) 79.3 (13.0)
Baseline systolic blood pressure 0.626
Mean(sd) 126.0 (14.4) 125.1 (15.3)
Baseline diastolic blood pressure 0.176
Mean(sd) 77.5 (10.5) 75.8 (10.5)
Baseline weight 0.949
Mean(sd) 85.6 (17.7) 85.7 (20.2)
Baseline Body Mass Index (BMI) 0.914
Mean(sd) 40.4 (32.9) 40.0 (27.9)
Baseline FTND 0.828
Mean(sd) 5.3 (2.4) 5.0 (2.4)
*significant difference between study arms † including those who gave all
reasons same importance
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intervention group as compared to the control group. At
12 months, the intervention group smoked 3.2 cigarettes
per day on average lower than the control group, but
such difference was not statistically significant (Table 4).
At 3 months, in the intervention group, stress at work
or in life was the main stated reason for not stopping
smoking (18.4%), followed by lack of motivation to quit
(9.2%), inability to attend all the follow-up sessions
(6.6%) and frequent travelling (6.6%). The most common
stated reasons for not stopping smoking in the control
group were stress at work or in life (26%), being around
other smokers (6.5%) and frequent traveling (6.5%).
The only variables that were associated predictors of
smoking as opposed to quitting at 12 months were years
of smoking and number of cigarettes per day. In
particular, the higher the number of years of smoking or
the number of cigarettes smoked per day, the more likely
the person relapsed and/or smoked at 12 months (RRR =
2.07, 95% CI 1.24, 3.45 p-value = 0.005 for Years of smok-
ing). On the other hand, only years of smoking predicted
dropping out as compared to quitting with similar trends
as those seen for smoking compared to quitting (RRR =
1.89, 95% CI, 1.17, 3.06 p-value = 0.009) (Table 5).
Discussion
This study was the first in Qatar, and probably in the
Middle East, to assess the effectiveness of pharmacist-led
smoking cessation program on smoking cessation rates.
The study explored the potential role that Qatar’s pri-
mary health care pharmacists could play in promoting
public health and disease prevention. Qatar pharmacists
are always accessible to the public without the need of
any prior appointment, and this allows them to oversee
the patients’ progress in smoking cessation programs.
The study helped to highlight the extent of contribution
that they could have in addressing this public health
burden in the country.
In the study, the smoking cessation rates in the inter-
vention group were better than those in the control
group; however this difference did not reach statistical
Table 2 Self-reported abstinence at each visit
Responders ITT
Variable Intervention Control p-value Intervention Control p-value
Outcome measure at 3 months
7 days abstinence 31/101 (30.7%) 26/98 (26.5%) 0.516 31/167 (18.6%) 26/147 (17.7%) 0.841
30 days abstinence 27/101 (26.7%) 22/98 (22.4%) 0.483 27/167 (16.2%) 22/147 (15.0%) 0.770
Continuous abstinence 25/101 (24.8%) 21/98 (21.4%) 0.578 25/167 (15.0%) 21/147 (14.3%) 0.864
Outcome measure at 6 months
7 days abstinence 28/100 (28.0%) 21/99 (21.2%) 0.324 28/167 (16.8%) 21/147 (14.3%) 0.546
30 days abstinence 27/100 (27.0%) 20/99 (20.2%) 0.259 27/167 (16.2%) 20/147 (13.6%) 0.525
Continuous abstinence 23/100 (23.0%) 20/99 (20.2%) 0.632 23/167 (13.8%) 20/147 (13.6%) 0.966
Outcome measure at 12 months
7 days abstinence 21/88 (23.9%) 14/83 (16.9%) 0.257 21/167 (12.6%) 14/147 (9.5%) 0.391
30 days abstinence 21/88 (23.9%) 14/83 (16.9%) 0.257 21/167 (12.6%) 14/147 (9.5%) 0.391
Continuous abstinence 21/88 (23.9%) 14/83 (16.9%) 0.257 21/167 (12.6%) 14/147 (9.5%) 0.391
Continuous abstinence at 12 months incorporating
data from visits 3 and 6 and 12‡
9/68 (13.2%) 6/68 (8.8%) 0.412 9/167 (5.4%) 6/147 (4.1%) 0.588
‡this includes only participants who completed assessment of all outcome measures up to the time indicated
Table 3 Analysis of the primary outcome of continuous abstinence at 12 months
Self-reported 12 months abstinence at
the final visit
Continuous abstinence at 12 months
(using all data from 3 visits)
OR (95% confidence interval) p-value OR (95% confidence interval) p-value
Unadjusted OR 1.54 (0.73, 3.29) 0.259 1.58 (0.53, 4.70) 0.414
Adjusted ORa 1.54 (0.80, 2.99) 0.196 1.58 (0.45, 5.58) 0.480
Adjusted ORb 1.62 (0.65, 4.04) 0.297 1.86 (0.49, 7.07) 0.364
Adjusted ORc 1.60 (0.65, 3.87) 0.306 1.60 (0.43, 5.90) 0.483
Adjusted ORd 1.37 (0.67, 2.80) 0.393 1.34 (0.47, 3.85) 0.589
aadjusted for clustering effect within pharmacists badjusted for years of smoking, cigarettes per day, tried quitting before, diabetes and nationality cadjusted for
the number of monitoring visits the participants attended dall those lost to follow up were considered as smokers
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significance. These findings are inconsistent with some
other pharmacist led smoking cessation studies con-
ducted elsewhere. For example, in one study from
United Kingdom (UK), 484 smokers were randomly
assigned to intervention and control groups in order to
evaluate the effectiveness of a structured pharmacist-
based smoking-cessation program compared with nor-
mal pharmaceutical service. At 12 months, 14.3% of
smokers in the intervention group were abstinent com-
pared with 2.7% in the control group (p < 0.001) [37]. In
a study in Australia, smoking quit rates achieved by par-
ticipants in a pharmacist-run smoking cessation pro-
gram, which was started in a hospital and continued in
either the community pharmacy or hospital setting, were
compared with quit rates in a minimal intervention
group. At 12 months, the 30-day point prevalence ab-
stinence rate was 22.9% for the hospital intervention
arm, 14.7% for the community pharmacy arm, and 3%
for the control arm (p = 0.031) [8]. In another study
conducted in the United States (US), smokers were ran-
domly assigned to receive a 3-session face-to-face group
program conducted by the pharmacist team or one 5- to
10-min standard care session delivered by the pharma-
cist team over the telephone. At 6 months, the biochem-
ically confirmed smoking cessation quit rate was 28% in
the face to face group and 11.8% in the standard care
group (p < 0.041) [11].
Yet our results were similar to other studies. For instance,
a study from Scotland evaluated the smoking quit rates of
participants who received smoking-cessation counseling
from trained pharmacists compared with standard phar-
macy advice. At 9 months, the continuous self-reported
smoking cessation rate was 11.6% in the intervention group
and 7.1% in the control group (p = 0.089) [38]. Another
study conducted in Australia assessed the effectiveness of a
hospital pharmacist-led multi-component smoking cessa-
tion program versus usual hospital care. The difference in
abstinence rates between intervention and control groups
was not statistically significant at 6 (11.6 versus 12.6%) or
12 months (11.6 versus 11.2%) [39].
Many factors could have contributed to the lack of sig-
nificant difference in smoking cessation rates between
the intervention and control groups in the study. One
such factor might be related to the pharmacy practice
environment in Qatar, where the pace of advancement
in community and ambulatory pharmacy practice has
been slow. With very few pharmaceutical care activities,
the scope of practice in Qatar is confined to filling pre-
scriptions and dispensing medications; although this is
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30–39 1.46 (0.38, 5.61) 0.584 1.58 (0.43, 5.83) 0.489
40–49 1.06 (0.25, 4.55) 0.934 0.66 (0.16, 2.79) 0.576
≥50 1.71 (0.29, 10.2) 0.554 1.85 (0.32, 10.56) 0.488
Marital Status
Never Married 1 1
Ever Married 0.50 (0.12, 2.08) 0.337 0.60 (0.15, 2.38) 0.465
Nationality
Qatar 1 1
Egypt 1.60 (0.49, 5.22) 0.432 0.58 (0.18, 1.84) 0.358
Other 1.60 (0.51, 5.03) 0.425 1.21 (0.41, 3.58) 0.734
Tried quitting before 0.77 (0.30, 1.99) 0.593 1.27 (0.49, 3.29) 0.619
Years of smoking 2.07 (1.25, 3.45) 0.005* 1.89 (1.17, 3.06) 0.009*
Cigarettes per day 1.04 (1.00, 1.09) 0.027* 1.01 (0.98, 1.05) 0.481
Study group 0.58 (0.24, 1.38) 0.218 0.70 (0.30, 1.64) 0.410
*significant association p < 0.05
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slowly, but surely, changing [40]. Pharmacy is still per-
ceived by the public as a profession that mainly focuses
on medication supplies and accessibility. To change this
perception and to recognize the pharmacist as a health-
care professional with a distinctive set of expertise and
abilities, more work has to be done; and Qatar’s Health
Strategy has already started steps towards launching pro-
grams leading in that direction.
In addition, although the intervention pharmacists re-
ceived a two day training workshop on smoking cessa-
tion, given the different educational backgrounds of
Qatar pharmacists and the cultural diversity of smokers
in Qatar, it seems that providing a more intensive smok-
ing cessation training with more rigorous follow-up and
mentorship would be warranted. This recommendation
is in line with one of the actions of Qatar Ministry of
Public Health’s Tobacco Cessation Action Plan, which is
capacity building and training of healthcare professionals
on counseling and care for tobacco users [23]. The pro-
posed training program should encompass aspects of
behavioral and pharmacological therapies and should ad-
dress elements of a personalized smoking cessation
action plan that takes into consideration the smoker’s
cultural background and his or her individual reasons
for quitting.
Although the study pharmacists reminded participants
several times about their follow-up visits, only 19% of
intervention participants attended all four visits as ori-
ginally planned in the study protocol. This may have de-
creased the effectiveness of the intervention as clinical
practice guidelines report that the more intensive the
treatment intervention is in duration or in number of
attended sessions the better is the smoking cessation
rate [5].
In addition, 61% of study participants had FTND score
of more than 5 which indicates high nicotine dependence.
Evidence suggests that high nicotine dependence is nega-
tively associated with making a quit attempt and is one of
the risk factors for relapse [41]. This may explain in part
the relatively low smoking cessation rates seen in the
study. The participants may have needed very specialized
interventions, a more intensive treatment or other potent
smoking cessation aids such as Varenicline and a closer
follow-up by the pharmacist to stop smoking.
An additional factor that might have contributed to
the insignificant differences in smoking cessation rates
between the two groups could be the fact that the
study pharmacists delivered care to participants in
both intervention and control groups. It is plausible
that the pharmacists, who were overall extremely mo-
tivated and enthusiastic, might have inadvertently
contaminated the usual care group with extra care.
This may have increased the smoking cessation rates
in this group.
Another potential factor could be related to the study
pre-calculated sample size and loss of follow-up rates.
The sample size in the study was estimated based on the
assumption of a 7-day point prevalence abstinence at
12 months of 3% for the control group. The abstinence
rate at 12 months for the control group in the study was
16.9% which is much higher than what has been previ-
ously estimated. In addition, 47.3% and 43.5% of patients
were lost to follow-up in intervention and control
groups respectively at 12 months. This may have re-
duced the study power and resulted in the lack of statis-
tically significant difference in smoking cessation rates
between the two groups. The high rate of loss of follow-
up in the study is not surprising. In spite of the tremen-
dous efforts of the study research assistants to contact
participants in both groups, many participants were not
reachable on the phone. However, there were no differ-
ences in the demographic or smoking related variables
between those who dropped and those who remained in
the study except for nationality. In particular, the per-
centage of dropouts among Qataris and other national-
ities was significantly higher than that among Egyptians
(51.2% vs 31.1% respectively). This observed difference
might have minimal to no impact on the study results
since adjusting for nationality and other variables pro-
duced no considerable change in the significance level
and the OR of the main comparison between the study
arms. Moreover, after adjusting for other variables,
nationality was not a predictor of dropping out of the
study. Yet this information is important for researchers
in future studies as they have to exert more efforts with
Qatari participants and participants of other nationalities
to decrease their dropout rates.
The top reason for continuing smoking in the inter-
vention group was stress at home or work. This is con-
sistent with findings from other pharmacist delivered
smoking cessation programs [42, 43]. A more intensive
and personalized approach by the pharmacist that
includes strategies on coping with stress may have im-
proved the smoking cessation rates in this group. The
number of cigarettes per day and the years of smoking
were found to be predictors of continuing smoking and
relapse at 12 months. This finding is consistent with pre-
vious studies that confirmed how challenging smoking
cessation is for smokers with high nicotine dependence
[41–44]. This would mean that a more intensive inter-
vention that could include collaboration with healthcare
providers from different disciplines, intense behavioral
therapy and more effective pharmacotherapy would have
enhanced cessation rates in this group of smokers.
In spite of the finding that the pharmacist-led smoking
cessation program was not significantly better in achiev-
ing smoking cessation rates compared with the control
group, the self-reported smoking cessation rates in the
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intervention arm were 24.8%, 23% and 23.9% at 3, 6 and
12 months respectively. These rates are similar to those
of other pharmacist led smoking cessation programs
conducted elsewhere [11, 13, 45, 46].
Furthermore, the smoking cessation rates obtained in
this study were higher than those obtained in smoking
cessation programs headed or facilitated by other health-
care professionals including physicians [47, 48]. In
addition, there was a significant reduction in the number
of cigarettes smoked daily between intervention and
control groups at 3 and 6 months. Therefore, despite
failing to detect a significant difference between the
intervention and the control groups, the study demon-
strated that a pharmacist-led smoking cessation program
can be implemented in Qatar and may hold promise
with some adjustments. The generated data may provide
the impetus to explore expanding the scope of pharmacy
practice in the country and for involving pharmacists in
providing smoking cessation counseling. As a follow-up
to this study, a qualitative study using semi-structured
interviews will be conducted with the study pharmacists
and a sample of the study participants in the interven-
tion arm to gain a deeper insight into the reasons behind
the lack of significant difference between the two groups,
the reasons for loss to follow-up, the barriers and chal-
lenges of the smoking cessation program and the
elements of an effective pharmacist delivered smoking
cessation program in Qatar.
Limitations
The study had important limitations that must be con-
sidered. A substantial number of participants had miss-
ing data on follow-up visits. Of a total of 314 patients
participated in the program; data were available for only
171 participants at 12 month follow-up visit. Only 8 of
the 35 participants who self-reported abstinence at
12 months had a final CO measurement as a result CO
measurement was not included in the main outcome as-
sessment. There is a possibility of a ‘Hawthorne effect’
which may have overestimated the self-reported quit
rates of participants in the usual care group.
Despite these limitations, the study had several strengths
including the use of a randomized control design, long
follow-up duration and use of intent-to- treat analysis.
Conclusions
A structured smoking cessation program with intensive
follow-up of smokers by trained ambulatory pharmacists
in Qatar has proven to be more effective than usual care
in reducing the number of daily smoked cigarettes at 3
and 6 months from the start of the program. However,
this reduction was not statistically significant after
12 months of follow-up. The self-reported smoking ces-
sation rates were higher in the structured program as
compared with the usual care group; but this difference
in rates between the groups didn’t reach statistical sig-
nificance. The results clearly illustrate the difficulty faced
by tobacco smokers to quit smoking for a prolonged
time despite structured and intensive efforts by pharma-
cists. This should not undermine the role of pharmacist
in smoking cessation in Qatar and what could be
achieved in reducing the smoking rate through intensive
follow-up and monitoring from pharmacist. More efforts
should be exerted to intensify this program and to
maximize the abstinence rate.
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